Anuh Pharma New Maharashtra Facility enhances production of high-potency APIs for regulated markets, complementing existing USFDA-compliant operations
Anuh Pharma New Maharashtra Facility : Key Expansion Highlights
✅ Location: Maharashtra (exact site undisclosed)
✅ Facility Type: API & formulation manufacturing block
✅ Strategic Focus: Enhanced capacity for regulated markets
✅ Compliance: USFDA/WHO-GMP standards
Project Details & Strategic Rationale
Manufacturing Capabilities
| Parameter | Specification |
|---|---|
| Product Focus | High-potency APIs & niche formulations |
| Market Target | US, EU, Japan regulated markets |
| Technology | Continuous manufacturing systems |
| Capacity Boost | 30-40% increase vs existing facilities |
Why Maharashtra?
✔ Cluster Benefits: Proximity to Mumbai port/regulatory hubs
✔ Skilled Workforce: Pharma talent pool availability
✔ State Incentives: Eligible for Maharashtra’s Pharma Policy subsidies
Leadership Commentary
“This expansion reinforces our commitment to becoming a global partner for complex pharmaceuticals while supporting India’s drug security goals.”
– Anuh Pharma Spokesperson
Market Context
- API Demand: Global market to reach $275B by 2027 (9% CAGR)
- India’s Position: Supplies 60% of global vaccines & 20% of generics
- Anuh’s Edge:
- 80+ DMF filings in regulated markets
- 30% revenue from high-margin oncology/ARV drugs
Project Timeline:
- Construction completion: Q4 2025
- Regulatory audits: H1 2026
- Commercial ops: Q3 2026
Existing Network:
- 5 manufacturing plants in India
- 3 USFDA-approved facilities
